German CMO Rentschler Biotechnologie GmbH is adding a 2,000 L single-use bioreactor to its facility in Laupheim, Germany, which it expects to be fully operational by the end of the first quarter of 2015.
Pressure on pharma ingredient supplier Lonza has continued into the
first half of the year, with consistently low use of custom
manufacturing capacity and weak demand for biomanufacturing
contributing to a 37 per cent drop in operating...